HLA-DRB1 Alleles Associated with Polymyalgia Rheumatica in Northern Italy: Correlation with Disease Severity

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 1999 May 4

PMID 10225816

Citations 9

Authors

C Salvarani

L Boiardi

V Mantovani

A Ranzi

F Cantini

I Olivieri

M Bragliani

E Collina

P Macchioni

Affiliations

Soon will be listed here.

Abstract

Objective: To examine the association of HLA-DRB1 alleles with polymyalgia rheumatica (PMR) in a Mediterranean country and to explore the role of HLA-DRB1 genes in determining disease severity.

Methods: A five year prospective follow up study of 92 consecutive PMR patients diagnosed by the secondary referral centre of rheumatology of Reggio Emilia, Italy was conducted. HLA-DRB1 alleles were determined in the 92 patients, in 29 DR4 positive rheumatoid arthritis (RA) patients, and in 148 controls from the same geographical area by polymerase chain reaction amplification and oligonucleotide hybridisation.

Results: No significant differences were observed in the frequencies of HLA-DRB1 types and in the expression of HLA-DRB 70-74 shared motif between PMR and controls. The frequency of the patients with double dose of epitope was low and not significantly different in PMR and in controls. No significant differences in the distribution of HLA-DR4 subtypes were observed between DR4+ PMR, DR+ RA, and DR4+ controls. Results of the univariate analysis indicated that an erythrocyte sedimentation rate (ESR) at diagnosis > 72 mm 1st h, the presence of HLA-DR1, DR10, rheumatoid epitope, and the type of rheumatoid epitope were significant risk factors associated with relapse/recurrence. Cox proportional hazards modelling identified two variables that independently increased the risk of relapse/recurrence: ESR at diagnosis > 72 mm 1st h (RR=1.5) and type 2 (encoded by a non-DR4 allele) rheumatoid epitope (RR=2.7).

Conclusion: These data from a Mediterranean country showed no association of rheumatoid epitope with PMR in northern Italian patients. A high ESR at diagnosis and the presence of rheumatoid epitope encoded by a non-DR4 allele are independent valuable markers of disease severity.

Citing Articles

Polymyalgia rheumatica: An update (Review).

Florescu M, Bobirca F, Florescu A, Padureanu V, Bobirca A, Ciurea P Exp Ther Med. 2023; 26(6):543.

PMID: 37928511 PMC: 10623218. DOI: 10.3892/etm.2023.12242.

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort.

Bolhuis T, Marsman D, van den Hoogen F, den Broeder A, den Broeder N, van der Maas A BMC Rheumatol. 2022; 6(1):45.

PMID: 35915465 PMC: 9344672. DOI: 10.1186/s41927-022-00274-y.

Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C Drugs Aging. 2019; 36(11):1015-1026.

PMID: 31493201 DOI: 10.1007/s40266-019-00705-5.

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis.

Smutny T, Barvik I, Veleta T, Pavek P, Soukup T J Clin Med. 2019; 8(5).

PMID: 31035618 PMC: 6572549. DOI: 10.3390/jcm8050582.

[S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and...].

Buttgereit F, Brabant T, Dinges H, Hiemer I, Kaplani M, Kiltz U Z Rheumatol. 2018; 77(5):429-441.

PMID: 29845555 DOI: 10.1007/s00393-018-0476-8.

References

Chuang T, Hunder G, Ilstrup D, Kurland L . Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982; 97(5):672-80. DOI: 10.7326/0003-4819-97-5-672. View

Salvarani C, Macchioni P, Boiardi L . Polymyalgia rheumatica. Lancet. 1997; 350(9070):43-7. DOI: 10.1016/S0140-6736(97)05001-0. View

Ayoub W, FRANKLIN C, Torretti D . Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985; 79(3):309-15. DOI: 10.1016/0002-9343(85)90309-2. View

Richardson J, Gladman D, FAM A, Keystone E . HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum. 1987; 30(11):1293-7. DOI: 10.1002/art.1780301113. View

Salvarani C, Macchioni P, Tartoni P, Rossi F, Baricchi R, Castri C . Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987; 5(3):205-15. View

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

Cid M, Ercilla G, Vilaseca J, Sanmarti R, Villalta J, Ingelmo M . Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum. 1988; 31(5):678-82. DOI: 10.1002/art.1780310515. View

Salvarani C, Macchioni P, Mantovani W, Rossi F, Veneziani M, Boiardi L . Extraarticular manifestations of rheumatoid arthritis and HLA antigens in northern Italy. J Rheumatol. 1992; 19(2):242-6. View

10.

Gabriel S, Sunku J, Salvarani C, OFallon W, Hunder G . Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997; 40(10):1873-8. DOI: 10.1002/art.1780401022. View

11.

Corrigall V, Dolan A, Dasgupta B, Panayi G . The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol. 1997; 36(9):976-80. DOI: 10.1093/rheumatology/36.9.976. View

12.

Combe B, Sany J, Le Quellec A, Clot J, Eliaou J . Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. J Rheumatol. 1998; 25(1):94-8. View

13.

Salvarani C, Macchioni P, Mantovani W, Bragliani M, Collina E, Cremonesi T . HLA-DRB1 alleles associated with rheumatoid arthritis in Northern Italy: correlation with disease severity. Br J Rheumatol. 1998; 37(2):165-9. DOI: 10.1093/rheumatology/37.2.165. View

14.

Salvarani C, Rossi F, Macchioni P, Mantovani W, Veneziani M, Boiardi L . Synovitis in polymyalgia rheumatica: an immunogenetic study. Br J Rheumatol. 1992; 31(10):720. DOI: 10.1093/rheumatology/31.10.720. View

15.

Thomson W, Pepper L, Payton A, Carthy D, Scott D, Ollier W . Absence of an association between HLA-DRB1*04 and rheumatoid arthritis in newly diagnosed cases from the community. Ann Rheum Dis. 1993; 52(7):539-41. PMC: 1005095. DOI: 10.1136/ard.52.7.539. View

16.

Weyand C, Hunder N, Hicok K, Hunder G, Goronzy J . HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum. 1994; 37(4):514-20. DOI: 10.1002/art.1780370411. View

17.

Weyand C, McCarthy T, Goronzy J . Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest. 1995; 95(5):2120-6. PMC: 295811. DOI: 10.1172/JCI117900. View

18.

Salvarani C, Boiardi L, Macchioni P, Rossi F, Tartoni P, Casadei Maldini M . Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis. 1995; 54(8):640-4. PMC: 1009961. DOI: 10.1136/ard.54.8.640. View

19.

Mantovani V, Martinelli G, Bragliani M, Buzzi M, Selva P, Collina E . Molecular analysis of HLA genes for the selection of unrelated bone marrow donor. Bone Marrow Transplant. 1995; 16(3):329-35. View

20.

Labbe P, Flipo R, Fajardy I, Hachulla E, Houvenagel E, Hatron P . [HLA DRB1 polymorphism in rhizomelic pseudo-polyarthritis and Horton disease]. Rev Med Interne. 1995; 16(10):778-81. DOI: 10.1016/0248-8663(96)80789-2. View